Alberto off to strong start in ‘09
This article was originally published in The Rose Sheet
Executive Summary
Alberto Culver books fiscal 2009 first-quarter sales of roughly $352.8 mil., up 2.8% on a reported basis, or 9.5% organically; pretax earnings, excluding restructuring costs, rose 24.5% to nearly $61 mil. Firm's domestic business grew 8% on strength of TRESemme and Nexxus, surpassing Unilever to become No. 3 in the U.S. hair-care sector, President and CEO Jim Marino notes during Jan. 26 call. International sales declined 5% on a reported basis due largely to a 24% negative currency impact, Alberto says, pointing out that TRESemme sales advanced double digits overseas. Nexxus also generated strong growth in the first quarter and currently is rolling out to Canada, with a launch in Chile targeted for later this year. Regarding Noxzema, acquired from Procter & Gamble in September 2007, Alberto is working on its integration "in addition to investing in consumer market research and actively developing a brand strategy that will better position [it] for 2010." Advertising and other marketing investments dropped 12.6% to $49.4 mil. in Q1, but the firm expects to up its investment as the year goes on. "We remain committed to our strategy of focusing on our key brands in our core markets while bringing innovation," Executive Chairman Carol Lavin Bernick states. Marino notes, however, that in the "very unique economic environment, it is impossible to predict how the remainder of this year will play out.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.